Remove 2022 Remove Clinical Pharmacology Remove Communication
article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

billion in 2022, the average projected return on investment (ROI) in R&D was just 1.2 Strengthening logistical capabilities One of the most unnecessary clinical trial burdens can be site inefficiencies, particularly where sites exist that do not recruit. Available from: [link] Worldwide cancer statistics [Internet].

article thumbnail

NHC Comments on Landmark FDA Guidance for Diversity in Clinical Trials

Putting Patients First Blog

This includes being aware of historical injustices that may have contributed to mistrust in the medical system and understanding the unique needs and concerns of different communities. Effective communication with diverse populations is essential for ensuring that all individuals can participate in clinical trials. Williams, S.,